| Literature DB >> 33133058 |
Chit Tong Lio1, Sandeep Kumar Dhanda2, Tanima Bose3.
Abstract
Dry eye disease (DED) can be represented as a display of disease in the mucosal part of the eye. It is quite distinct from the retinal side of the eye which connects with the neurons and thus represents the neuroimmunological disease. DED can occur either by the internal damage of the T cells inside the body or by microbial infections. Here we summarize the most common animal model systems used for DED relating to immune factors. We aimed to identify the most important immune cell/cytokine among the animal models of the disease. We also show the essential immune factors which are being tested for DED treatment. In our results, both the mechanism and the treatment of its animal models indicate the involvement of Th1 cells and the pro-inflammatory cytokine (IL-1β and TNF-α) related to the Th1-cells. The study is intended to increase the knowledge of the animal models in the field of the ocular surface along with the opening of a dimension of thoughts while designing a new animal model or treatment paradigm for ocular surface inflammatory disorders.Entities:
Keywords: animal models; dry eye disease; helper T cells; inflammation; therapy
Mesh:
Substances:
Year: 2020 PMID: 33133058 PMCID: PMC7550429 DOI: 10.3389/fimmu.2020.01930
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
FIGURE 1Flowchart of study selection process. The process originates with 2463 studies from searching through several databases. A total of 57 studies are selected for meta-analysis after evaluation and exclusion.
Excluded immune factors and the corresponding studies.
| De Paiva 2006_TNFα | 812.90323 |
| De Paiva 2010_TGFβ | 9654.30464 |
| De Paiva 2010_CCL20 | 68.96188 |
| De Paiva 2010_IFNγ | 60.12935 |
| Yoon 2007_CCR5 | 478.87324 |
| Yoon 2007_CCR3 | −107.81889 |
| Huang 2018_IL23R | 54.19355 |
| Huang 2018_IL21 | 894.19355 |
| Huang 2018_CCL20 | 3603.87097 |
| Huang 2018_IFNγ | 180.64516 |
| Joossen 2016_IL2 | 234.83871 |
| Joossen 2016_IL12 | 1345.80645 |
FIGURE 2Meta-analysis of different immune factors in animal models for dry eye disease. (A) The global standardized mean difference for each of the immune factors is obtained by our proposed meta-analysis is represented by the blue square in the forest plot. The 95% confidence interval is shown by the interval line across the blue squares. DS mice has the highest SMD among all animal models, followed by CBA/J mice with TNF-α. Forest plots for each of the models are shown in the Supplementary Figures S1–S15. (B) The standardized mean difference of immune factor for each model that is most expressed. IL-17A is the highest in DS mice and TNF-α in CBA/J mice.
FIGURE 3Radar plots showing the relationships between each animal models and groups of immune factors. Immune factors are grouped into 3 groups (Group A, major immune cells; Group B, major cytokine and chemokine markers; Group C, functions overlying on multiple cell types). Each color represents different animal model. The standardized mean difference between disease model and control from the meta-analysis for each immune factors in different animal models are plotted in radar plots (see Supplementary Material). Each circle in the radar plots represents an increasing of 1 in SMD. Th-Cs, T helper cells; Tc-Cs, T cytoxic cells; Tr-Cs, T resident cells; gb-Cs, gb cells; NT, neutrophils; PB, plasmablasts; NKC, natural killer cells; MC, mast cells; LCs, langerhans cells; MP, macrophages; B-Cs:, B cells; DCs, dendritic cells; PT, platelets.
FIGURE 4Pie chart showing the proportion of studies that include treatment for dry eye disease. Each treatment used in the studies are represented by one color. The number in the pie chart shows the number of studies that used the type of molecules to evaluate treating effect. MK2I, MK2 inhibitors; LPAR1/3A, LPAR1/3 antagonists.
Studies contain treatment effect.
| ( | Betaine, L-carnitine, erythritol | Osmoprotectants | C57BL/6 mice |
| ( | Pioglitazone (PIO) | PPAR-γ antagonist | C57BL/6 mice |
| ( | Mixed medicinal plant extracts | Plant extract | C57BL/6 mice |
| ( | Cyclosporine A (CsA) | Amino acid | Albino rabbit |
| ( | Novel antagonist GW559090 | Integrin-α4 antagonist | TSP-1 null mice |
| ( | Corticosteroids, doxycycline | Inflammation inhibitors | C57BL/6 mice |
| ( | Epigallocatechin gallate (EGCG), hyaluronic acid | Inflammation inhibitors | Albino rabbit |
| ( | Amygdalin | Bioactive compound | Sprague-Dawley rats |
| ( | Apricot kernel extract | Plant extract | Sprague-Dawley rats |
| ( | HL036 | TNFα blocker | C57BL/6 mice |
| ( | Cyclosporine A (CsA) | Amino acid | Wistar rats |
| ( | Restasis and dexamethasone | Inflammation inhibitor | Wistar rats |
| ( | Novel antagonist GW559090 | Integrin-α4 antagonist | C57BL/6 mice |
| ( | Topical TSG-6 | Inflammation inhibitors | NOD.B10.H2b |
| ( | Adiponectin | Inflammation inhibitors | C57BL/6 mice |
| ( | Vasoactive intestinal peptide (VIP) | Neuropeptide | NOD mice |
| ( | FK506 | Inflammation inhibitors | CBA/J mice |
| ( | Ki16425 | LPAR1/3A | NOD mice |
| ( | Polygonum cuspidatum (PCE) | Plant extract | Wistar rats |
| ( | S31-201 | STAT3 inhibitor | C57BL/6 mice |
| ( | α-Melanocyte-stimulating hormone | Inflammation inhibitors | Wistar rats |
| ( | CM-hUCESC | Stem cells | Albino rabbit |
| ( | Epigallocatechin gallate (EGCG), hyaluronic acid | Inflammation inhibitors | Albino rabbit |
| ( | MK2i | Inflammation inhibitors | C57BL/6 mice |